Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.
Journal: Future oncology (London, England)
Published: July 31, 2026
First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.
Journal: Advances in therapy
Published: December 04, 2025
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.
Journal: Cancer research communications
Published: October 14, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.
Journal: Annals of hepatology
Published: October 03, 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study.
Journal: Journal of hepatology
Published: November 12, 2024
Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA.
Journal: Future oncology (London, England)
Published: August 19, 2024
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis.
Journal: Future oncology (London, England)
Published: February 14, 2024
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: March 18, 2023
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240.
Journal: Therapeutic advances in medical oncology
Published: March 11, 2021
Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity.
Journal: Journal of gastrointestinal oncology
Published: June 12, 2019
Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates.
Journal: Molecular cancer therapeutics
Published: March 05, 2019
Last Updated: 09/26/2026